As of 2026-04-09, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (13.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.90 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -273.8%.
The range of the Relative Valuation is (9.81) - (15.00) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 18.3x | 16.9x |
| Forward P/E multiples | 10.0x - 17.5x | 15.0x |
| Fair Price | (9.81) - (15.00) | (13.73) |
| Upside | -224.2% - -289.9% | -273.8% |
| Date | P/E |
| 2026-04-06 | -9.11 |
| 2026-04-02 | -9.36 |
| 2026-04-01 | -8.71 |
| 2026-03-31 | -8.93 |
| 2026-03-30 | -7.66 |
| 2026-03-27 | -7.83 |
| 2026-03-26 | -8.08 |
| 2026-03-25 | -8.12 |
| 2026-03-24 | -7.80 |
| 2026-03-23 | -8.02 |
| 2026-03-20 | -7.88 |
| 2026-03-19 | -8.19 |
| 2026-03-18 | -8.05 |
| 2026-03-17 | -8.65 |
| 2026-03-16 | -8.66 |
| 2026-03-13 | -8.90 |
| 2026-03-12 | -8.88 |
| 2026-03-11 | -9.07 |
| 2026-03-10 | -9.32 |
| 2026-03-09 | -9.24 |
| 2026-03-06 | -9.51 |
| 2026-03-05 | -9.50 |
| 2026-03-04 | -9.72 |
| 2026-03-03 | -9.16 |
| 2026-03-02 | -9.09 |
| 2026-02-27 | -9.75 |
| 2026-02-26 | -10.16 |
| 2026-02-25 | -10.45 |
| 2026-02-24 | -9.99 |
| 2026-02-23 | -12.67 |
| 2026-02-20 | -12.80 |
| 2026-02-19 | -13.65 |
| 2026-02-18 | -12.73 |
| 2026-02-17 | -12.41 |
| 2026-02-13 | -12.37 |
| 2026-02-12 | -12.64 |
| 2026-02-11 | -12.65 |
| 2026-02-10 | -12.03 |
| 2026-02-09 | -11.91 |
| 2026-02-06 | -11.34 |
| 2026-02-05 | -11.11 |
| 2026-02-04 | -11.52 |
| 2026-02-03 | -12.21 |
| 2026-02-02 | -12.48 |
| 2026-01-30 | -12.49 |
| 2026-01-29 | -12.73 |
| 2026-01-28 | -12.20 |
| 2026-01-27 | -12.73 |
| 2026-01-26 | -12.70 |
| 2026-01-23 | -12.51 |